ISPOR EU 2024: Expert strategies to transform evidence and value-based outcomes

Our expert team will be at ISPOR EU 2024 in Barcelona, Booth #1412. Our specialists in global and US policy, access, value, and evidence are eager to discuss ways to advance and accomplish your strategic goals. 

 

 

 

Gain insights from our 34 research posters accepted for ISPOR.

We are proud to have 34 research posters accepted for ISPOR EU 2024. View our research at Booth #1412 or contact us for a deeper discussion, tailored to your specific needs. Our research posters at ISPOR EU 2024 span a broad range of insights, including: 

 

Increasing collaboration between stakeholders — navigating the impact of policy changes

Recent trends from UK’s cancer drugs fund, key drivers of acceptance HTA197 Comparison of ‘coverage with evidence development’ approaches for digital health technologies and pharmaceuticals MT31 Contrasting evidence requirements for early access schemes for DHTs in the UK and Germany: a challenge for multi-market evidence generation planning MT16 The devil in the detail: the challenges of evaluating patient access to medicines HPR107 Analysis of pharmaceutical company actions in Asia-Pacific to improve patient access OP6 Real-world evidence in action: a review of Australia’s health technology assessment (HTA) of non-drug health technologies MT2 Evolving national HTA frameworks in the Asia-Pacific region: a targeted literature & stakeholder review of HTA processes in Australia, Japan, and South Korea HTA72 Next-generation sequencing-based circulating tumor DNA testing: clinical drivers versus market access reality MT69 Insights on early access refusal in France HTA28

 

Capturing and demonstrating holistic value and patient impact under increasing evidence   demands

Determining if Delphi panel qualitative insights can be useful when informing drug pricing-related decisions in the drug development stage SA18 Addressing postnatal depression: disparities in treatment availability HSD59 Postnatal depression: an underestimated humanistic burden in maternal health PCR86 How does real-world evidence support regulatory and HTA agency assessments and beyond? RWD183 NICE quality-adjusted life years severity modifier: what have we learned so far HTA282 Is there enough focus on capturing health-related quality of life perspectives of pediatric patients and their caregivers in non-oncology indications? PCR81 Exploring the impact of changes in health valuation post-COVID-19 pandemic on existing cost-effectiveness analyses EE485 How has treatment switching been accounted for? Insights from NICE appraisals HTA106 Defining value in the mental illness space: how are patient preferences accounted for in health technology assessments of treatments for depression and schizophrenia? HTA45 Integrating healthcare system value into new innovations for timely and full patient access HPR160

 

Join us for our panel discussion: Refining value assessment by considering indirect costs

Date and time: Tuesday, November 19, 11:45 AM
Panel: 219
Theme: Discover the benefits of broadening the scope of value assessment by incorporating evidence on the indirect burden of disease. We’ll explore its application in US value assessment and ex-US Health Technology Assessment (HTA) submissions.

Key discussion points

• Rare diseases often require a significant amount of medical care, which leads to a higher burden of direct medical costs.
• Indirect costs—such as productivity loss, absenteeism, lifestyle disruptions, and family and societal impacts—contribute to the overall burden of patients with rare disease and their caregivers.
• These broad indirect impacts are often overlooked and under-measured, leading to underestimation of the total disease burden in evidence used for value assessments and HTA submissions.

What you’ll learn

• Recent research measuring the indirect burden of disease
• How real-world evidence on indirect costs can be applied to value assessment and HTA submissions
• The potential impact of incorporating these insights on healthcare decision making